Today: 11 April 2026
Subscribe
Browse Category

Pharmaceutical Industry 13 November 2025 - 5 December 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and Epilepsy Breakthroughs as Stock Hits New High on December 5, 2025

Praxis Precision Medicines shares jumped nearly 40% intraday on December 5 after its pivotal epilepsy trial was stopped early for efficacy and the company reported a positive pre-NDA meeting with the FDA for its essential tremor drug. By late morning, PRAX traded around $265–266, hitting a new 52-week high and pushing its market cap above $1.1 billion. The stock is up over 200% year-to-date.
5 December 2025
·
Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck (MRK) Stock Outlook on December 4, 2025: Dividend Hike, Legal Setback and New Growth Drivers

Merck shares closed at $100.86 on December 4, down 1.4%, with after-hours trading flat. Scotiabank raised its price target to $120, echoing similar moves by Goldman Sachs and Wells Fargo. Keytruda sales rose 10% in Q3 to $8.1 billion, but Gardasil fell 24% amid weaker China demand. The stock’s market cap stands near $250 billion.
4 December 2025
··
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. shares surged to $13–15 by early afternoon December 4, more than doubling from the previous close of $7.09, after hitting intraday highs above $18. The rally followed news of a manufacturing milestone for its PL‑14 allergy nasal spray and new preclinical data showing improved mucoadhesion for its naloxone hydrogel. Polyrizon, based in Israel, has no approved products and reported a 2024 net loss of about $1.5 million.
4 December 2025
··
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics shares surged over 500% on December 3, 2025, after its Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met all primary and key secondary endpoints. The trial showed a 54% slowing of upper limb decline and 91% preservation of heart function versus placebo. Capricor plans to resubmit its BLA to the FDA, addressing a previous Complete Response Letter. The stock traded around $39–40 intraday, up from $6.36.
3 December 2025
···
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

A U.S. federal judge allowed a $6.7 billion lawsuit against Bristol-Myers Squibb over its 2019 Celgene acquisition to proceed, rejecting the company’s motion to dismiss key claims. BMY shares closed at $49.18 on December 1, up 7–8% over five days, but remain down for the year. The company’s annual dividend yield is about 5%. New cell therapy approvals and strong ASH 2025 hematology data also drew investor attention.
2 December 2025
·
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer shares closed at $25.74 on November 28, 2025, down 1.8% over the past year. Regulatory filings show new institutional buying, and the company completed a Metsera acquisition worth up to $10 billion. Pfizer reduced its BioNTech stake by 54.7% and raised its full-year EPS guidance to $3.00–$3.15 after reporting $16.7 billion in Q3 revenue.
30 November 2025
····
Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck & Co. (MRK) Stock News Today: Keytruda Wins, $9.2 Billion Cidara Deal and Fresh Highs — November 29, 2025

Merck shares closed at $104.83 on November 28, just below the 52-week high of $105.84 set earlier in the week after a Wells Fargo upgrade. The stock is up about 21% over the past month and 8% year-to-date. Scotia Capital and Level Four Advisory Services have trimmed their Merck holdings, according to new filings. Merck continues to warn investors about an unsolicited mini-tender offer from Tutanota LLC at $65 per share.
29 November 2025
·
Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly (LLY) Stock Dips After Trillion‑Dollar Surge: November 29, 2025 Update for Investors

Eli Lilly shares fell 2.61% to about $1,075.47 on November 29, 2025, continuing a pullback from record highs reached earlier in the month. The company’s market cap stands near $989 billion, with shares still up roughly 43% for the year after a surge fueled by strong Q3 results and demand for obesity drugs. Trading volume was around 2.73 million shares. The stock remains priced at a P/E ratio above 50.
29 November 2025
··
Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck (MRK) Stock Rallies as Big Money Moves In and Dividend Rises – November 28, 2025 Update

Merck shares closed near $104.5 on Friday, close to a 52-week high, with market cap near $260 billion. Norges Bank disclosed a new $2.86 billion stake, while Groupama, SEB, and Boston Partners trimmed holdings. The stock jumped 21% in the past month, buoyed by new oncology approvals and bullish research. Merck’s trailing 12-month revenue stands at about $64 billion, with net income near $19 billion.
28 November 2025
···
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie shares fell 1.9% to $227.41 in early U.S. trading Wednesday, pulling back from recent highs after a strong run. The drop follows new Medicare drug price cuts targeting two AbbVie drugs and comes days after FDA approval of EPKINLY combo therapy for follicular lymphoma. Year to date, the stock is up about 30%.
26 November 2025
··
PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

PFE Stock Today (Nov. 25, 2025): Pfizer Rises on Metsera Obesity Deal, PADCEV Approval and Options Surge

Pfizer shares rose 1.7% to $25.65 by early afternoon Tuesday after the company completed a $10 billion acquisition of obesity-drug developer Metsera. The stock traded between $25.24 and $25.96, with a market cap near $143 billion. Pfizer also reported new FDA approval for PADCEV plus Keytruda in bladder cancer and continued strong options activity at the $25 strike.
25 November 2025
···
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Altimmune shares traded near $5.10 on November 25, up about 20% over two weeks after Phase 2b data for lead drug pemvidutide was published in The Lancet and highlighted at AASLD. The stock remains down over 50% from its December 2024 high, with investor sentiment tempered by ongoing shareholder lawsuits and a new $400 million shelf registration.
25 November 2025
··
Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson (JNJ) Stock on November 25, 2025: Ex‑Dividend Day, Options Surge and a $3 Billion Cancer Bet

Johnson & Johnson traded near $206 per share on Monday, just below its 12-month high, ahead of Tuesday’s key ex-dividend date for a $1.30 per share payout. The stock is up over 7% in November, outpacing the broader market. Options activity spiked Monday, with call volume jumping 468% to about 201,000 contracts. JNJ’s market cap stands just under $500 billion.
25 November 2025
···
Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly closed Friday at about $1,060 per share, briefly topping a $1 trillion market cap—the first drugmaker to do so. Institutional filings released Sunday show Coldstream Capital raised its stake by 43.5% in Q2, while Charles Schwab Investment Management increased holdings to 5.36 million shares. LLY is up over 35% year-to-date, driven by demand for its GLP-1 obesity drugs.
23 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly closed Friday, November 21, 2025, with a market value near $1 trillion, the first drugmaker to reach that mark. Shares ended around $1,060, just below their all-time high. The surge follows strong demand for its obesity and diabetes drugs, which now generate over $10 billion in quarterly sales. Year-to-date, the stock is up about 36%.
22 November 2025
··
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer and Tris Pharma agreed to pay $41.5 million to settle Texas claims over adulterated ADHD drug Quillivant XR. Pfizer also announced a research deal with Nona Biosciences for antibody discovery. At the Jefferies Healthcare Conference, management reaffirmed $7.7 billion in cost cuts and a push into obesity drugs. PFE traded near $25.37 early Wednesday, slightly down from the prior close.
19 November 2025
····
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Novo Nordisk slashed the self-pay price of Wegovy and most Ozempic doses from $499 to $349 per month, effective Nov. 17, 2025. New patients can access starter doses for $199 monthly for two months. The move follows White House deals expanding Medicare and Medicaid coverage for obesity drugs and comes as telehealth firms launch competing $199 offers.
17 November 2025
·
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock shares surged 26% to $37.98 after an FDA meeting on its SMA therapy and the launch of a $200 million at-the-market stock offering. The company reported a Q3 2025 net loss of $102.2 million, up from $64.5 million a year earlier, with no revenue as it prepares for a potential U.S. launch in 2026. Trading volume topped 2.7 million shares.
14 November 2025
····
Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics (OTLK) Soars as FDA Accepts ONS‑5010 BLA and Sets December 31, 2025 Review Date

Outlook Therapeutics shares rose about 22% after the FDA accepted its resubmitted Biologics License Application for ONS‑5010/LYTENAVA as a treatment for wet AMD, setting a PDUFA review date of December 31, 2025. The FDA classified the filing as a complete, Class 1 response, triggering a 60-day review. The move follows an August rejection over insufficient efficacy data. ONS‑5010/LYTENAVA is already approved in the EU and UK.
13 November 2025
··
1 … 5 6 7 8

Stock Market Today

  • JD.com Shares Show Signs of Value After Prolonged Weakness
    April 10, 2026, 6:42 PM EDT. JD.com's stock price around $28.93 is drawing attention after years of declines, including a 17.8% fall over the past year and a 57.3% drop over five years. The Chinese e-commerce giant shows mixed short-term returns but remains under pressure amid a tough China tech sector. A Discounted Cash Flow (DCF) analysis, which estimates intrinsic value based on future cash flows, suggests JD.com is undervalued by 53.6%, putting fair value near $62.29 per share. The company's price-to-earnings (P/E) ratio stands at 13.8, below the retail industry average of 20.5, implying the stock trades at a discount relative to earnings. Investors weigh the recovery potential against ongoing risks in China's market and tech regulation environment.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 6:45 PM EDT JD.com Shares Show Signs of Value After Prolonged Weakness April 10, 2026, 6:42 PM EDT. JD.com's stock price around $28.93 is drawing attention after years of declines, including a 17.8% fall over the past year and a 57.3% drop over five years. The Chinese e-commerce giant shows mixed short-term returns but remains under pressure amid a tough China tech sector. A Discounted Cash Flow (DCF) analysis, which estimates intrinsic value based on future cash flows, suggests JD.com is undervalued by 53.6%, putting fair value near
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Go toTop